Please enable Javascript
Advanced Urothelial Carcinoma
Advertisement
Biomarkers of TRAEs in Patients With Advanced UC Treated With EV: Analysis of the UNITE Study
Amanda Nizam, MD
Advanced Urothelial Carcinoma
|
November 20, 2023
Dr. Nizam provides an overview of her recent research on biomarkers of TRAEs associated with EV for aUC.
View More
Panel Shares Predictions for What’s to Come in Advanced Urothelial Carcinoma
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
View More
Panelists Share Best Practices, Strategies for Community Oncologists Managing Patients on EV/Pembro
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
View More
Bladder Panel Talks Treatment Sequencing and Decisions in Different Patient Cases
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
View More
Combination Antibody-Drug Conjugate Strategy and the Future of Bladder Treatment
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
View More
Reactions to Phase 3 THOR Study: Primary End Point Not Met
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares lessons learned from the phase THOR study.
View More
Bladder Panel Offers Insights on CheckMate 901 Study and Optimal Duration of Immunotherapy Treatment
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discusses the CheckMate 901 study results.
View More
EV-302 Results and How They Compare to the JAVELIN Paradigm
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
View More
Bladder Panel Reacts to EV-302 Data Presented at ESMO 2023
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discusses the "buzz" around the EV-302 study.
View More
Panel Discusses Unmet Needs in Advanced Urothelial Carcinoma
Peter O'Donnell, MD
Roundtable
|
November 13, 2023
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
View More
ESMO Congress Round-Up With Dr. Evan Yu: EV-302 and CheckMate 901
Evan Yu, MD
Advanced Urothelial Carcinoma
|
November 2, 2023
Dr. Evan Yu opines on whether the EV-302 and CheckMate 901 data are practice-changing and when to recommend each combo.
View More
EV-302/Keynote-A39: A “Landmark Achievement”
Akhil Abraham Saji, MD
Advanced Urothelial Carcinoma
|
November 1, 2023
This is the first trial that has shown an OS benefit improvement over chemo in the 1L mUC setting, a landmark achievement.
Read More
Does the Addition of Lenvatinib to Pembrolizumab Improve Outcomes in Advanced Urothelial Carcinoma?
Zachary Bessette
Advanced Urothelial Carcinoma
|
November 1, 2023
Lenvatinib plus pembrolizumab versus pembrolizumab alone as a first-line therapy for patients with advanced UC.
Read More
Phase 3 THOR Study: Erdafitinib Provides OS Benefit Over Chemotherapy
Emily Menendez
Advanced Urothelial Carcinoma
|
October 27, 2023
Erdafitinib was found to significantly improve OS and boost benefit over chemotherapy in patients with FGFRalt advanced/mUC.
Read More
Urothelial Carcinoma at ESMO: THOR, DAD, and Other Trials of Note
Brad McGregor, MD
ESMO 2023
|
October 25, 2023
Drs. McGregor, Sonpavde highlight the Double Antibody Drug conjugate trial, updates from THOR, and other studies.
View More
EV-302 and CheckMate 901: Comparing the Practice-Changing ESMO Data for Metastatic UC
Brad McGregor, MD
ESMO 2023
|
October 25, 2023
Drs. McGregor, Sonpavde share how the data compare across CheckMate 901 and EV-302, as well as considerations for physicians.
View More
ICRA Trial Finds Synergy Between Paclitaxel, Tremelimumab for mUC
Emily Menendez
ESMO 2023
|
October 24, 2023
Paclitaxel administered with tremelimumab provided encouraging antitumor activity with a manageable safety profile.
Read More
New Standard of Care: EV/Pembro Significantly Improves Survival in Previously Untreated la/mUC
Zachary Bessette
ESMO 2023
|
October 23, 2023
The practice-changing results were presented at ESMO 2023.
Read More
CheckMate 901: Nivolumab Plus Gemcitabine-Cisplatin for Untreated mUC
Zachary Bessette
ESMO 2023
|
October 23, 2023
Nivolumab plus gemcitabine-cisplatin demonstrated meaningful improvements in OS and PFS as first-line treatment of mUC.
Read More
Phase 1 DAD Trial: Sacituzumab Govitecan Plus Enfortumab Vedotin Safe, Feasible for mUC
Emily Menendez
ESMO 2023
|
October 18, 2023
The combination of sacituzumab govitecan plus enfortumab vedotin was found to be safe, and provides a high ORR.
Read More
Load More
Advertisement
Advertisement
Advertisement